Skip to content
Clinical Trials – home
RecruitingRare disease

A Study to Test the Safety and Effectiveness of TAK-360 in People with Narcolepsy without Cataplexy

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study is looking at a condition called Narcolepsy without Cataplexy, also known as NT2. This is a sleep disorder where people experience excessive daytime sleepiness and may suddenly fall asleep during the day, but they do not have sudden muscle weakness or loss of muscle control that can occur in other forms of narcolepsy. The treatment being tested is called TAK-360, which is an experimental medication given as a tablet by mouth. Some participants will receive TAK-360 while others will receive placebo. The purpose of this study is to evaluate the safety and tolerability of TAK-360.

During the study, participants will take TAK-360 or placebo for a period of 4 weeks. The study will look at whether any unwanted effects occur during treatment. The study will also measure changes in daytime sleepiness using a questionnaire called the Epworth Sleepiness Scale, which asks about how likely someone is to fall asleep in different situations. Additionally, a test called the Maintenance of Wakefulness Test will be used, which measures how well someone can stay awake in a quiet, comfortable setting. These measurements will be compared between the group taking TAK-360 and the group taking placebo to see if there are any differences.

Participants in this study will be adults between 18 and 70 years old who have been diagnosed with NT2. The study uses a design where neither the participants nor the doctors know who is receiving the actual medication and who is receiving placebo until the study is completed. This helps ensure that the results are measured fairly and without bias. The study will continue for several weeks and will involve regular visits to check on safety and how well the treatment is working.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Treatment period with study medication

    During this phase, you will receive either TAK-360 or placebo (a tablet that looks identical but contains no active medication). The assignment will be random, and neither you nor the medical staff will know which one you are receiving.

    You will take the medication by mouth in the form of tablets.

    This treatment period will last for 4 weeks.

  2. Step 2

    Baseline assessments

    At the beginning of the study, measurements will be taken to establish your starting point. These baseline values will be used for comparison with later results.

    Your level of daytime sleepiness will be assessed using the Epworth Sleepiness Scale, which is a questionnaire that measures how likely you are to fall asleep in different situations.

    Your ability to stay awake will be measured using the Maintenance of Wakefulness Test, which records how long you can remain awake in a quiet, comfortable setting.

  3. Step 3

    Week 4 assessments

    After 4 weeks of treatment, the same assessments will be repeated.

    The Epworth Sleepiness Scale will be completed again to measure any changes in your daytime sleepiness compared to the baseline.

    The Maintenance of Wakefulness Test will be performed again to measure any changes in your ability to stay awake compared to the baseline.

  4. Step 4

    Safety monitoring throughout the study

    Throughout the entire study period, you will be monitored for any side effects or adverse events.

    Any health problems or symptoms that occur during the trial will be recorded and evaluated by the medical team.

    This monitoring is done to assess the safety and tolerability of the study medication.

Who can join the trial?

4 criteria

  • You must be between 18 and 70 years old at the time of signing the consent form
  • You must weigh at least 40 kilograms
  • Your body mass index (a number calculated from your weight and height) must be between 16 and 38
  • You must have a confirmed current diagnosis of narcolepsy without cataplexy, which is a sleep disorder that causes excessive daytime sleepiness without sudden muscle weakness

Who cannot join the trial?

3 criteria

  • The source data does not provide specific exclusion criteria, which are reasons why a patient cannot participate in the study
  • Without detailed exclusion criteria listed, it is not possible to specify which medical conditions, medications, or other factors would prevent someone from joining this clinical trial
  • Typically, exclusion criteria may include things like other serious health problems, use of certain medications, pregnancy, or recent participation in other studies, but these specific details are not available in the provided information
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • TAK-360

    is an investigational medication being studied for the treatment of narcolepsy without cataplexy. This is an experimental drug that is being tested to see if it is safe and effective for people who have narcolepsy but do not experience cataplexy, which is a sudden loss of muscle control. The trial will look at different amounts of this medication to find the best dose that works well and is safe for patients to take.

  • Placebo

    is an inactive substance that looks like the real medication but contains no active treatment. It is used in this study to compare against TAK-360 to help researchers understand if the actual medication is working better than no treatment at all.

What is already known about the treatment

TAK-360 – TAK-360 is an investigational medication currently being studied in clinical trials and is not yet approved for general medical use. It is being tested as a potential treatment for narcolepsy without cataplexy, which is a sleep disorder that causes excessive daytime sleepiness but does not include the sudden muscle weakness seen in other forms of narcolepsy. The exact way TAK-360 works in the body at the molecular level has not been publicly disclosed, as it is still in the research phase where scientists are evaluating whether it is safe, well-tolerated by patients, and effective in reducing symptoms of this sleep condition. The medication is being tested in different doses to find the most appropriate amount that provides benefits while minimizing side effects.

Investigated diseases

Narcolepsy without Cataplexy – This is a chronic sleep disorder characterized by excessive daytime sleepiness and sudden, uncontrollable episodes of falling asleep during the day. People with this condition experience overwhelming drowsiness and may fall asleep at inappropriate times, such as during work or conversations. Unlike narcolepsy with cataplexy, individuals with this form do not experience sudden loss of muscle tone triggered by emotions. The disorder disrupts the normal sleep-wake cycle, making it difficult to maintain alertness throughout the day. Nighttime sleep is often fragmented and disturbed, though the person sleeps for normal or extended periods. This condition significantly impacts daily functioning, work performance, and social activities.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-517711-70-01Protocol codeTAK-360-2001Estimated enrolment147 patientsSponsorTakeda Development Center Americas Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).